Acetyl-L-Carnitine (ALCAR) for Parkinson's Disease
Also known as: ALCAR, ALC, Levacecarnine
ALCAR's mitochondrial support and neurotrophic effects target dopaminergic neuron energy failure in Parkinson's.
Mechanism of Action
ALCAR enhances mitochondrial β-oxidation in dopaminergic neurons, supports Complex I function, and promotes BDNF expression. Its antioxidant properties protect against dopamine auto-oxidation toxicity in the substantia nigra.
General mechanism: Acetylated amino acid derivative. Mitochondrial fatty acid transport, acetyl group donor for acetylcholine synthesis, neurotrophic factor enhancer.
Current Evidence
Preclinical studies show neuroprotection in MPTP models. Small clinical studies show improvement in fatigue and depression in PD. No large disease-modification trials.
Clinical Status: Preclinical positive. Small clinical studies for PD-related fatigue.
Safety Profile
Very safe. GI effects possible. May increase seizure frequency in susceptible individuals. Fishy body odor at high doses.
Key Research Questions
- Can ALCAR slow dopaminergic neuron loss as an adjunct to levodopa?
- Does ALCAR address PD-related fatigue through mitochondrial enhancement?